Ophthalmic Innovation

Advancing the industry’s most comprehensive ophthalmic surgical and pharmaceutical pipeline

At Glaukos, we are dedicated to addressing the greatest unmet needs of the global ophthalmic market, for physicians and for patients. That’s why we’ve spent more than a decade re-investing in R&D and clinical trial programs to develop and advance a deep pipeline of novel therapies currently being evaluated in FDA clinical trials, while leading the industry in clinical support and patient education resources. And it’s why we’re seeking to leverage our platform technologies to build an unrivaled portfolio of next-generation surgical and pharmaceutical therapies in glaucoma, corneal health, and retinal disease.

We’ve achieved many firsts in clinical studies and over the past several years, Glaukos has reinvested approximately 30% of all sales back into research and development activities – all to relentlessly advance our goal of creating and delivering transformative therapies for patients struggling with eye diseases and the skilled surgeons dedicated to their healing.

Product Pipeline

Our Strategy for Long-Term Growth

Pipeline Currently Includes 15 Candidates, Plus Additional Undisclosed Programs

Micro-Surgical Devices

Product/CandidatePlatform/Product
Type
Targeted
Indication
Status
Product/CandidateiStent Platform/Product
Type
Trabecular Bypass Stents
Targeted
Indication
Approved
Product/CandidateiStent inject / iStent inject W Platform/Product
Type
Trabecular Bypass Stents
Targeted
Indication
Approved
Product/CandidateiStent SA Platform/Product
Type
Trabecular Bypass Stents
Targeted
Indication
Pivotal IDE Trial
Product/CandidateiStent infinite Platform/Product
Type
Trabecular Bypass Stents
Targeted
Indication
FDA Submission
Product/CandidateiPRIME Platform/Product
Type
Viscodelivery
Targeted
Indication
PMA non-approvable; review ongoing
Product/CandidatePreserFlo (Santen) Platform/Product
Type
Microshunt
Targeted
Indication
FDA Submission
Pre-Clinical Phase 1 Phase 2 Phase 3 FDA Submission Approved1

Pharmaceuticals

Product/CandidatePlatform/Product
Type
Targeted
Indication
Status
Product/CandidateiDose TR Platform/Product
Type
Sustained-Release System
Targeted
Indication
Phase 3
Product/CandidateiDose TREX Platform/Product
Type
Sustained-Release System
Targeted
Indication
Pre-clinical
Product/CandidateiDose ROCK Platform/Product
Type
Sustained-Release System
Targeted
Indication
Pre-clinical
Product/CandidateiLink® Epi-off (Photrexa) Platform/Product
Type
Bio-Activated
Targeted
Indication
Approved
Product/CandidateiLink® Epi-on (Epioxa) Platform/Product
Type
Bio-Activated
Targeted
Indication
Phase 3
Product/CandidateiLink® Epi-on Next Generation Platform/Product
Type
Bio-Activated
Targeted
Indication
Pre-clinical
Product/CandidateDry Eye Candidate Platform/Product
Type
Eyelid Transdermal Platform
Targeted
Indication
Pre-clinical
Product/CandidatePresbyopia Candidate Platform/Product
Type
Eyelid Transdermal Platform
Targeted
Indication
Pre-clinical
Product/CandidateMulti-Kinase Inhibitor SR Platform/Product
Type
Bio-Erodible
Targeted
Indication
Pre-clinical
Product/CandidateTriamcinolone Acetonide SR Platform/Product
Type
Bio-Erodible
Targeted
Indication
Pre-clinical
Product/CandidateAnti-VEGF SR Platform/Product
Type
Bio-Erodible
Targeted
Indication
Pre-clinical
Pre-Clinical Phase 1 Phase 2 Phase 3 FDA Submission Approved1

Biosensors

Product/CandidatePlatform/Product
Type
Targeted
Indication
Status
Product/CandidateIOP Sensor Platform/Product
Type
Implantable sensor
Targeted
Indication
Pre-clinical
Pre-Clinical Phase 1 Phase 2 Phase 3 FDA Submission Approved1

*2019 Glaukos fiscal year

1 In US